Cervical Cancer Chemoradiotherapy Outcomes

DFS was defined as the time from the initial diagnosis (histology) to disease recurrence or death from any cause. OS was defined as the time from initial diagnosis (histology) to death from any cause. PC is defined as the absence of local and nodal disease within the pelvis. LC was defined as the absence of disease in postoperative hysterectomy region, upper vagina, and parametria on gynecologic examination at follow-up. Data regarding patients with no evidence of recurrence or death were censored at the date of the last follow-up. Follow-up was defined as the time from the end of treatment to the relevant event (death from any cause, cancer-specific death, any recurrence, local recurrence, and pelvic recurrence).
All toxicity data were scored using the Common Terminology Criteria of Adverse Events (CTCAE) version 4.0.
Gastrointestinal (GI) and genitourinary (GU) radiotherapy-related toxicities were categorized into acute (symptoms experienced during or ≤ 3 months of completion of CRT-S) and chronic (> 3 months after CRT-S).
Surgical morbidity and mortality were evaluated and registered during hospitalization and postoperative (acute, ≤ 6 weeks postoperative) and at every visit thereafter (late). Based on CTCAE v4, the following data were extracted: urinary infection, wound infection, urinary fistula, digestive fistula, ileus, bowel subobstruction, and thromboembolic events.
Pathology results were analyzed with regard to resection margins and pathological response (residual tumor was defined as ≥ 10 mm grossly and < 10 mm microscopically); they were also compared with the imaging performed after CRT.